College of Public Health, The Ohio State University.
Columbus State Community College.
Milbank Q. 2024 Sep;102(3):605-631. doi: 10.1111/1468-0009.12705. Epub 2024 Jun 11.
Policy Points Workers' compensation agencies have instituted opioid review policies to reduce unsafe prescribing. Providers reported more limited and cautious prescribing than in the past; both patients and providers reported collaborative pain-management relationships and satisfactory pain control for patients. Despite the fears articulated by pharmaceutical companies and patient advocates, opioid review programs have not generally resulted in unmanaged pain or reduced function in patients, anger or resistance from patients or providers, or damage to patient-provider relationships or clinical autonomy. Other insurance providers with broad physician networks may want to consider similar quality-improvement efforts to support safe opioid prescribing.
Unsafe prescribing practices have been among the central causes of improper reception of opioids, unsafe use, and overdose in the United States. Workers' compensation agencies in Washington and Ohio have implemented opioid review programs (ORPs)-a form of quality improvement based on utilization review-to curb unsafe prescribing. Evidence suggests that such regulations indeed reduce unsafe prescribing, but pharmaceutical companies and patient advocates have raised concerns about negative impacts that could also result. This study explores whether three core sets of problems have actually come to pass: (1) unmanaged pain or reduced function among patients, (2) anger or resistance to ORPs from patients or providers, and (3) damage to patient-provider relationships or clinical autonomy.
In-depth semistructured interviews were conducted with 48 patients (21 from Washington, 27 from Ohio) and 32 providers (18 from Washington, 14 from Ohio) who were purposively sampled to represent a range of injury and practice types. Thematic coding was conducted with codebooks developed using both inductive and deductive approaches.
The consequences of opioid regulations have been generally positive: providers report more limited prescribing and a focus on multimodal pain control; patients report satisfactory pain control and recovery alongside collaborative relationships with providers. Participants attribute these patterns to a broad environment of opioid caution; they do not generally perceive workers' compensation policies as distinctly impactful. Both patients and providers comment frequently on the difficult aspects of interacting with workers' compensation agencies; effects of these range from simple inconvenience to delays in care, unmanaged pain, and reduced potential for physical recovery.
In general, the three types of feared negative impacts have not come to pass for either patients or providers. Although interacting with workers' compensation agencies involves difficulties typical of interacting with other insurers, opioid controls seem to have generally positive effects and are generally perceived of favorably.
政策要点 工人赔偿机构制定了阿片类药物审查政策,以减少不安全的处方。与过去相比,提供者报告的限制和谨慎处方更多;患者和提供者都报告了协作性疼痛管理关系和患者满意的疼痛控制。尽管制药公司和患者权益倡导者表达了担忧,但阿片类药物审查计划一般不会导致患者疼痛未得到控制或功能下降、患者或提供者愤怒或抵制、或损害患者-提供者关系或临床自主权。其他拥有广泛医生网络的保险公司可能希望考虑类似的质量改进措施,以支持安全的阿片类药物处方。
不安全的处方做法一直是美国阿片类药物使用不当、使用不安全和过量的主要原因之一。华盛顿州和俄亥俄州的工人赔偿机构实施了阿片类药物审查计划(ORP)--一种基于利用审查的质量改进形式--以遏制不安全的处方。有证据表明,这些规定确实减少了不安全的处方,但制药公司和患者权益倡导者提出了可能产生的负面影响的担忧。本研究探讨了三个核心问题是否确实已经出现:(1)患者的疼痛未得到控制或功能下降,(2)患者或提供者对 ORP 的愤怒或抵制,(3)患者-提供者关系或临床自主权受损。
对 48 名患者(华盛顿州 21 名,俄亥俄州 27 名)和 32 名提供者(华盛顿州 18 名,俄亥俄州 14 名)进行了深入的半结构式访谈,这些患者和提供者是为了代表各种损伤和实践类型而有目的地抽取的。使用归纳和演绎方法开发的代码簿进行主题编码。
阿片类药物法规的后果总体上是积极的:提供者报告的处方限制更多,并且注重多模式疼痛控制;患者报告满意的疼痛控制和恢复,同时与提供者建立协作关系。参与者将这些模式归因于阿片类药物谨慎的广泛环境;他们一般不认为工人赔偿政策有明显的影响。患者和提供者都经常评论与工人赔偿机构互动的困难方面;这些影响从简单的不便到护理延误、疼痛未得到控制和身体恢复潜力降低不等。
总的来说,患者和提供者都没有出现三种担心的负面影响。尽管与工人赔偿机构互动涉及到与其他保险公司互动的典型困难,但阿片类药物控制似乎产生了普遍积极的影响,并且普遍受到好评。